Key Highlights
- Elevance Health (NYSE:ELV) earned USD 6.99 per share in adjusted terms, up 15.9%, as its benefit expense ratio improved to 90.6% from 91.3%, and raised 2026 adjusted EPS guidance to at least USD 29.00.
- Molina Healthcare (NYSE:MOH) beat revenue estimates at USD 11.08 billion, but GAAP EPS fell 52% to USD 0.73 as its medical care ratio rose to 92.9%, and the shares dipped about 4%.
- Medpace (NASDAQ:MEDP) earned USD 4.84 per share against USD 4.44 expected and raised EPS guidance, but its revenue outlook fell below expectations and the shares slid.
- All three reported on Wednesday, October 21, 2026, and in each case the driver beneath reported EPS, the claims ratio for the insurers and revenue guidance for the trial outsourcer, set the reaction.
Elevance Health (NYSE:ELV): lower claims costs and a higher floor
Elevance Health (NYSE:ELV), one of the largest US health insurers and the operator of Anthem plans, reported third-quarter results on Wednesday, October 21, 2026. Adjusted EPS rose 15.9% to USD 6.99, well above consensus estimates, and GAAP EPS rose 17.9% to USD 6.27. Total revenue grew 1.4% to USD 51.4 billion, while medical membership fell 1.1% to 44.9 million. The benefit expense ratio, the share of premiums paid in medical claims, improved to 90.6% from 91.3%. Elevance raised 2026 guidance to at least USD 29.00 in adjusted EPS and guided to growth of at least 12% in 2027 from a baseline of at least USD 26.75.
Profit growth came from lower claims costs relative to premiums and from services rather than revenue. A 70 basis point improvement in the ratio, on roughly USD 43 billion of Health Benefits segment revenue, is worth about USD 300 million in quarterly margin on simple arithmetic. The segment still earned only a 1.0% margin, down from 1.4%, partly on one-time investments. CarelonRx, the pharmacy benefit manager, lifted operating gain 10.8% to USD 616 million, and Carelon Services grew operating gain 33.3% to USD 292 million.
The first risk is that cost trend reaccelerates, since a 90.6% ratio leaves a thin buffer against higher hospital and drug use. Policy is the second: Medicaid eligibility, Medicare Advantage rates and exchange subsidies could shift after the midterm elections. Membership, down 487,000 year on year, limits premium growth, and pharmacy benefit managers face scrutiny of their pricing practices. The company bought back USD 330 million of stock in the quarter, and a dividend of USD 1.72 is payable on Friday, December 18, 2026.
Molina Healthcare (NYSE:MOH): a Medicaid squeeze on thin margins
Molina Healthcare (NYSE:MOH), a managed care company focused on government-sponsored health plans, released third-quarter results on Wednesday, October 21, 2026. Total revenue was USD 11.08 billion, down about 3% but above consensus estimates. GAAP net income dropped 52% to USD 38 million, or USD 0.73 per share, and adjusted EPS fell 53% to USD 0.89 from USD 1.84. The consolidated medical care ratio rose to 92.9% from 92.6%, and membership fell about 13.6% to 4.86 million, with Marketplace enrolment down to 267,000 from 713,000. The shares dipped after the release, with market data showing declines of about 4%.
The medical care ratio is the core profit lever. With an adjusted administrative cost ratio of 6.3%, a ratio of 92.9% leaves, on simple arithmetic, under one cent of margin per premium dollar before investment income. Medicaid, about 4.37 million of the members, ran at 93.0%, 100 basis points worse than a year earlier, while Marketplace improved to 92.5% from 95.6%. Chief executive Joseph Zubretsky said Molina was "likely observing the beginning of the turn in Medicaid margins", citing 2027 rate updates, which states set to reflect recent cost trends.
Full-year guidance of at least USD 5.25 in adjusted EPS was reaffirmed, and it absorbs about USD 1.50 per share of fourth-quarter losses from a new Florida Medicaid contract and about USD 1.00 from an exited Medicare product. The main risk is that 2027 Medicaid rates lag cost trend and keep the segment near 93%. Parent company cash of about USD 608 million, up from USD 223 million at the end of 2025, gives some cushion.
Medpace (NASDAQ:MEDP): a margin beat against a softer revenue guide
Medpace (NASDAQ:MEDP), a contract research organisation that runs clinical trials for mainly small and mid-sized biotechnology companies, reported third-quarter results after the close on Wednesday, October 21, 2026. Earnings were USD 4.84 per share against a consensus estimate of USD 4.44, a beat of about 9% on simple arithmetic. Revenue was USD 716.0 million, broadly in line with to slightly above consensus estimates depending on the measure. Margin expansion did most of the work. The company raised 2026 EPS guidance above consensus, but its revenue guidance came in below expectations, and the shares slid.
Revenue is the cleaner read on demand, because it follows the pace at which sponsors start and run trials. A contract research organisation recognises revenue as work is performed, so a softer outlook can point to slower study starts, delays or cancellations. Earnings can rise even when activity slows, through cost control, a favourable mix of work and buybacks, so investors treat a beat built on margins as lower quality than one built on volume. The logic mirrors the insurers: the line beneath reported EPS set the reaction.
Medpace relies on biotechnology sponsors whose spending depends on access to equity and venture capital, and those funding conditions tighten when rates rise, as they did after the Fed hike on Wednesday, September 16, 2026. The first risk is that the revenue shortfall reflects weaker funding that feeds into awards and backlog over several quarters. The second is margin durability, since gains driven by cost savings may be harder to repeat.
Where Things Stand
The answer is that each stock traded on the ratio beneath its earnings line. Elevance Health (NYSE:ELV) lifted its EPS floor to at least USD 29.00 because its benefit expense ratio improved 70 basis points to 90.6%, while Molina Healthcare (NYSE:MOH), heavier in Medicaid, saw its ratio rise to 92.9% and its GAAP EPS fall 52%. Medpace (NASDAQ:MEDP) beat by about 9% on margins, but a revenue guide below expectations signalled slower trial demand from rate-sensitive biotechnology sponsors. The next catalysts are the Fed decision on Wednesday, October 28, 2026, the midterm elections on Tuesday, November 3, 2026, Medicare enrolment closing on Monday, December 7 and 2027 state Medicaid rate updates. Guidance is a company forecast, not a guarantee, and this is not investment advice.






Please wait processing your request...